Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, ProcedurelessTM intragastric balloon for weight loss, ...